Why Intellia Therapeutics, Inc.’s (NTLA) Stock Is Up 5.06%
As of Tuesday, October 27, Intellia Therapeutics, Inc.’s NTLA share price has surged by 5.06%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Intellia Therapeutics, Inc.’s (NTLA) Stock Is Down 5.29%
As of Tuesday, October 13, Intellia Therapeutics, Inc.’s NTLA share price has dipped by 5.29%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Intellia Therapeutics, Inc.’s (NTLA) Stock Is Up 6.06%
As of Tuesday, September 22, Intellia Therapeutics, Inc.’s NTLA share price has surged by 6.06%, which has investors questioning if this is right time to sell.Michael Rose
Why Intellia Therapeutics, Inc.’s (NTLA) Stock Is Up 5.31%
As of Thursday, September 17, Intellia Therapeutics, Inc.’s NTLA share price has surged by 5.31%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Intellia Therapeutics, Inc.’s (NTLA) Stock Is Up 7.72%
As of Tuesday, August 25, Intellia Therapeutics, Inc.’s NTLA share price has surged by 7.72%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | NTLA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,720.8 | $227.8 | 53% |
|
| Shares Out (Mil) | 133.5 | 53.4 | 68% |
|
| Institutional Ownership | 98.4% | 92.9% | 78% |
|
| Float (Mil) | 134.2 | 41.2 | 66% |
|
| Beta | 1.82 | 0.95 | 89% |
|
| Avg Daily Volume (000s) | 4,306 | 513 | 91% |
|
| Price Change (52-week) |
(52.0%) | 47.3% | 19% |
|
| Growth | NTLA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.1% | 12.8% | 28% |
|
| Net Income (5yr) | (25.2%) | (10.1%) | 17% |
|
| EPS (5yr) | (9.7%) | 15.8% | 22 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.7%) | (15.7%) | 43% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 16 | 17 | 17 | |
| Current EPS | ($0.786) | ($3.144) | ($2.565) | |
| Month Ago EPS | ($0.789) | ($3.157) | ($2.599) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.780) | ($3.141) | ($1.758) | |
| Year/Year Chg | (1.6%) | (17.4%) | (57.9%) | |
| Financials | NTLA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $60 | $37 | 21% |
|
| Net Income (TTM) (Mil) | ($400) | ($44) | 4% |
|
| EPS (TTM) | ($3.344) | ($1.500) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($347) | ($34) | 2% |
|
| Net Cash Flow (TTM) (Mil) | ($49) | $2 | 20% |
|
| Long-Term Debt (Q1) (Mil) | $50 | $4 | 39% |
|
| Enterprise Value (Q1) (Mil) | $1,146 | $177 | 42% |
|
| Valuation | NTLA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.36 | 2.22 | 60% |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NTLA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (374.4%) | 66.9% | 1% |
|
| Net Margin | (672.2%) | (75.3%) | 1% |
|
| ROA | (45.6%) | (47.1%) | 12% |
|
| ROE | (55.4%) | (53.3%) | 14% |
|
| Liabilities to Assets | 15.1% | 29.3% | 9% |
|
| F-Score | 6 | 2 | 67% |
|
Intellia Therapeutics, Inc. did not pass any screens on 10/27/2026.
